
Nateglinide
CAS No. 105816-04-4
Nateglinide ( A-4166 | SDZ-DJN 608 )
产品货号. M10264 CAS No. 105816-04-4
那格列奈是一种口服降血糖药,用于治疗非胰岛素依赖型糖尿病(NIDDM)。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
10MG | ¥332 | 有现货 |
![]() ![]() |
25MG | ¥672 | 有现货 |
![]() ![]() |
50MG | ¥1199 | 有现货 |
![]() ![]() |
100MG | ¥2017 | 有现货 |
![]() ![]() |
200MG | ¥2908 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称Nateglinide
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述那格列奈是一种口服降血糖药,用于治疗非胰岛素依赖型糖尿病(NIDDM)。
-
产品描述Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those na?ve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound.(In Vitro):Nateglinide inhibits typical recordings of dinitrophenol-induced KATP currents in a concentration-dependent manner. Nateglinide exhibits IC50 values of 7.4 μM and 2.4 μM for 5 mM glucose (G5) and 16 mM (G16) glucose, respectively.(In Vivo):Nateglinide (50mg/kg, orally in mice) stimulates human C-peptide secretion in the humanized mice and improved postprandial glucose concentrations.
-
体外实验Nateglinide inhibits typical recordings of dinitrophenol-induced KATP currents in a concentration-dependent manner. Nateglinide exhibits IC50 values of 7.4 μM and 2.4 μM for 5 mM glucose (G5) and 16 mM (G16) glucose, respectively. RT-PCR Cell Line:Rat pancreatic β-cells.Concentration:0-100 μM.Incubation Time:~20 min.Result:Produced a complete inhibition of KATP current at concentration of 3 μM.
-
体内实验Nateglinide (50mg/kg, orally in mice) stimulates human C-peptide secretion in the humanized mice and improved postprandial glucose concentrations. Animal Model:Mice.Dosage:50mg/kg.Administration:Orally at 60min before oral administration of 4 g/kg glucose.Result:Stimulates human C-peptide secretion.
-
同义词A-4166 | SDZ-DJN 608
-
通路Cell Cycle/DNA Damage
-
靶点Potassium Channel
-
受体Potassium Channel| PPARγ
-
研究领域Cardiovascular Disease
-
适应症——
化学信息
-
CAS Number105816-04-4
-
分子量317.42
-
分子式C19H27NO3
-
纯度>98% (HPLC)
-
溶解度Ethanol: 63 mg/mL (198.47 mM); DMSO: 63 mg/mL (198.47 mM)
-
SMILESO=C(O)[C@@H](CC1=CC=CC=C1)NC([C@H]2CC[C@H](C(C)C)CC2)=O
-
化学全称(R)-2-((1r,4R)-4-isopropylcyclohexanecarboxamido)-3-phenylpropanoic acid
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Hu S, et al. J Pharmacol Exp Ther. 2000 May;293(2):444-52.
产品手册




关联产品
-
CHET3
CHET3 is a highly selective allosteric activator for TASK-3-containing K2P channels. CHET3 has shown potent in vivo analgesic effects in various acute and chronic pain models in rodents.
-
BL-1249
BL-1249 是一种非甾体抗炎剂 (NSAID) 和钾通道激活剂,可有效激活 K2P2.1 (TREK-1) 和 K2P10.1 (TREK-2),EC50 值分别为 5.5 μM 和 8.0 μM。BL-1249 在细胞外激活了所有 TREK 亚家族成员,但对其他 K2P 亚家族没有影响。BL-1249 对膀胱的选择性 (EC50 为 1.26 μM) 比对血管组织 (EC50 为 21.0 μM) 更高。
-
BMS-394136
BMS-394136 是一种有效的选择性 IKur/Kv1.5 抑制剂。